Assessment of reasons for overactive bladder treatment change

Castro, D.; Miranda, P.; Sánchez-Ballester, F.; Arumí, Daniel; Ebel, Christine

doi:10.1016/s2173-5786(11)70022-1

Cited by 17 publications

(9 citation statements)

References 26 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…This was a post-hoc analysis of data from a retrospective, cross-sectional observational and multicenter study (IMPACTA), aimed at determining the factors causing treatment change in OAB patients and the resulting degree of satisfaction under normal conditions [32]. …”

Section: Methodsmentioning

confidence: 99%

“…In this sense, non-interventional studies, may provide complementary information on the effectiveness of specific treatments in real clinical practice settings [31]. Then, data from open-label or observational studies exploring the subjective patient perception of the effectiveness of fesoterodine, in symptomatic OAB subjects not satisfied with tolterodine, would also be relevant to clinical management in the daily practice [8,32]. …”

Section: Introductionmentioning

confidence: 99%

“…Here, we carried out a post-hoc analysis from the IMPACTA study [32] to evaluate whether aging and dose escalation to fesoterodine 8 mg compared to fesoterodine 4 mg, were associated with higher patient-reported treatment benefit and clinician perception of change, after switching from their first OAB tolterodine ER-based therapy, in daily clinical practice.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

et al. 2012

View full text Add to dashboard Cite

Section: Methodsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

et al. 2012

View full text Add to dashboard Cite

“…A Clinical Global Impression (CGI) egy klasszikus eszköz a beteg állapotának globális értékelésére külön-böző betegségekben, OAB-gyógyszer-vizsgálatban is alkalmazták [6,7,8]. A CGI-vel mérhető a beteg jelen tüneteinek súlyossága (severity -CGIs) és a javulás a kiindulási állapothoz képest (improvement -CGIi).…”

Section: A Betegség Súlyossága Az Orvos Véleménye Alapján Cgiunclassified

Health related quality of life and productivity of women with overactive bladder

et al. 2012

View full text Add to dashboard Cite

A kutatás célja hiperaktív hólyagszindrómával élő nők életminőségének és munkaképességének vizsgálata. Módszer: A szerzők keresztmetszeti kérdőíves vizsgálatot végeztek öt szakambulancia bevonásával. Felmérték az általános egészségi állapotot (EQ-5D), a betegségspecifi kus életminőséget (King's Health Questionnaire) és a munkaképessé-get (Work Productivity and Activity Impairment) validált kérdőívekkel vizsgálták. Eredmények: A 61 nőbeteg átlag 57,7 (SD = 11,6) éves, a tünetek 6,6 (SD = 6,2) éve kezdődtek, 57 (93%) betegnél vizeletinkontinenciával társul. Az EQ-5D index átlaga 0,668 (SD = 0,314), az átlagos lakossági értéknél nem szignifi kánsan alacsonyabb (p>0,05). A betegségspecifi kus életminőség-csökkenés az inkontinencia hatása és a fi zikai korlátozottság területeken a legkifejezettebb (átlag 70,5, illetve 68,9), a King's Health Questionnaire-ből számolt hasznosságérték átlag 0,932 (SD = 0,029). A munkaképesség az aktív dolgozóknál: távollét 0,04% (SD = 0,11), csökkent munkavégzés 43,64% (SD = 28,54), munkavégzés korlátozottsága összesen 40,97% (SD = 26,91), egyéb tevékenységek 47,72% (SD = 27,24). Következtetések: Az EQ-5D és a King's Health Questionnaire hasznosság mérceként való alkalmazhatóságá-nak vizsgálatára hiperaktív hólyagszindrómában további kutatások szükségesek. A kezelés hatásosságának értékelé-séhez érdemes fi gyelembe venni a munkavégzés korlátozottságának változását. Orv. Hetil., 2012, 153, 1068-1076. Kulcsszavak: hiperaktív hólyagszindróma, vizeletinkontinencia, életminőség, munkaképesség Health related quality of life and productivity of women with overactive bladderThe objektive of the research was to assess the health related quality of life and productivity of women with overactive bladder. Methods: A cross-sectional survey was performed in 5 outpatient centers. General health status (EQ-5D), disease-specifi c quality of life (King's Health Questionnaire) and productivity (Work Productivity and Activity Impairment) were assessed. Results: Sixty-one women with mean age of 57.7 (SD = 11.6) years have had symptoms for 6.6 (SD = 6.2) years and 57 (93%) had incontinence. The EQ-5D (mean 0.668, SD = 0.314) was not signifi cantly lower than that of the average population (p>0.05). The impact of incontinence and physical limitation (mean 70.5 and 68.9, respectively) were signifi cant, the King's Health Questionnaire-utility was 0.932 (SD = 0.029). Productivity scores of involved patients were: absenteeism 0.04% (SD = 0.11), presenteeism 43.64% (SD = 28.54), overall work impairment 40.97% (SD = 26.91), and other activities 47.72% (SD = 27.24). Conclusions: Applicability of the EQ-5D and King's Health Questionnaire as utility measures in overactive bladder deserve further research. Presenteeism should be considered in the evaluation of the therapy. Orv. Hetil., 2012Hetil., , 153, 1068Hetil., -1076

show abstract

“…Adherence studies on patients using antimuscarinics have shown that approximately 60–80% of patients discontinue treatment within a year . Reasons for discontinuation include lack of efficacy and unwanted side effects . In theory, combination drug therapy with two or more drugs may be used to increase efficacy (reduction of OAB symptoms) or decrease drug‐specific adverse events.…”

Section: Introductionmentioning

confidence: 99%

What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014

Visco

Fraser

Newgreen

et al. 2016

Neurourol. Urodynam.

View full text Add to dashboard Cite

Combination therapy is reasonable when monotherapy has suboptimal efficacy or bothersome side effects. Future research studies evaluating combination therapy for urgency urinary incontinence should ideally(1) be performed as part of a randomized clinical trial,(2) evaluate non-responders to monotherapy,(3) evaluate combination therapy using medications with different mechanisms of action,(4) include clinically meaningful and patient reported outcomes when evaluating efficacy, and(5) include cost-effectiveness analyses to justify any increased cost by showing improvement in efficacy or reduction in side effects.

show abstract

Assessment of reasons for overactive bladder treatment change

Cited by 17 publications

References 26 publications

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Dose and aging effect on patients reported treatment benefit switching from the first overactive bladder therapy with tolterodine ER to fesoterodine: post-hoc analysis from an observational and retrospective study

Health related quality of life and productivity of women with overactive bladder

What is the role of combination drug therapy in the treatment of overactive bladder? ICI-RS 2014

Contact Info

Product

Resources

About